OBJECTIVES: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. RESULTS: In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98-0.99). CONCLUSION: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.

Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen Aberdeen UK

Amsterdam Rheumatology and Immunology Center Amsterdam The Netherlands

Amsterdam UMC University of Amsterdam Department of Rheumatology and Clinical Immunology and Department of Experimental Immunology Amsterdam Institute for Infection and Immunity Amsterdam The Netherlands

Center for Rheumatic Diseases University of Medicine and Pharmacy Romanian Registry of Rheumatic Diseases Bucharest Romania

Center for Rheumatology and Spine Diseases Copenhagen Center for Arthritis Research Denmark

Center for Treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway

Centre for Rheumatology Research Landspitali University Hospital Reykjavik Iceland

Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

DANBIO Registry Rigshospitalet Glostrup Denmark

Department for Rheumatology and Immunology Inselspital University Hospital Bern on behalf of the Swiss Clinical Quality Management for Rheumatic Diseases SCQM Zürich Switzerland

Department for Science and Research Landspitali University Hospital Reykjavik Iceland

Department of Clinical Medicine Aarhus University Aarhus Denmark

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Clinical Sciences Lund Rheumatology Skåne University Hospital Lund University Lund Sweden

Department of Medicine Solna Karolinska Institutet Stockholm Sweden

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Rheumatology Aarhus University Hospital Aarhus Denmark

Department of Rheumatology and Inflammation Research Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden

Department of Rheumatology Ankara Yıldırım Beyazıt University Ankara City Hospital Ankara Turkey

Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia

Department of Rheumatology Geneva University Hospital Geneva Switzerland

Department of Rheumatology Hospital de Santa Maria CHULN Instituto Medicina Molecular Faculdade de Medicina da Universidade de Lisboa Centro Académico de Medicina de Lisboa Lisbon Portugal

Department of Rheumatology Satakunta Central Hospital Rauma Finland

Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

Departments of Medicine and Rheumatology Helsinki University Hospital Helsinki Finland

Division of Rheumatology Department of Internal Medicine Dokuz Eylul University School of Medicine Izmir Turkey

Faculty of Medicine University of Iceland Reykjavik Iceland

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Institute of Rheumatology Prague Czech Republic

Research Unit Sørlandet Hospital Kristiansand Norway

Reuma pt Sociedade Portuguesa de Reumatologia Lisbon Portugal

Rheumatology Unit Department of Medical Sciences and Public Health AOU and University of Cagliari Monserrato Italy

Rheumatology Unit DETO University of Bari Bari Italy

Serviço de Reumatologia Hospital Garcia de Orta Almada Portugal

Zobrazit více v PubMed

Gossec L, Baraliakos X, Kerschbaumer A. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700–12. PubMed PMC

Brahe CH, Ørnbjerg LM, Jacobsson L. et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment – results from 12 countries in EuroSpA. Rheumatology (Oxford) 2020;59:1640–50. PubMed

Scrivo R, Giardino AM, Salvarani C. et al. An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. Clin Exp Rheumatol 2020;38:107–14. PubMed

Ogdie A, Palmer JL, Greenberg J. et al. Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J Rheumatol 2019;46:475–82. PubMed

Flouri ID, Markatseli TE, Boki KA. et al. Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence. J Rheumatol 2018;45:785–94. PubMed

Iannone F, Lopriore S, Bucci R. et al. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 2015;44:192–9. PubMed

Fagerli KM, Lie E, Van Der Heijde D. et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73:132–7. PubMed

Chimenti MS, Perricone C, Graceffa D. et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol 2012;30:23–30. PubMed

Glintborg B, Østergaard M, Dreyer L. et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382–90. PubMed

Saad AA, Ashcroft DM, Watson KD. et al.; BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010;49:697–705. PubMed PMC

Saber TP, Ng CT, Renard G. et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94. PubMed PMC

Kristensen LE, Gülfe A, Saxne T, Geborek P.. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364–9. PubMed

Vieira-Sousa E, Eusébio M, Ávila-Ribeiro P. et al. Real-world longterm effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the rheumatic diseases Portuguese register. J Rheumatol 2020;47:690–700. PubMed

Michelsen B, Sexton J, Wierød A. et al. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: data from the observational multicentre NOR-DMARD study. Semin Arthritis Rheum 2020;50:12–6. PubMed

Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ.. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 2015;1:e000017. PubMed PMC

Iannone F, Santo L, Anelli MG. et al. Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 2017;47:108–14. PubMed

Eder L, Chandran V, Schentag CT. et al. Time and predictors of response to tumour necrosis factor-(alpha) blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology 2010;49:1361–6. PubMed

Mease PJ, Coates LC.. Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 2018;47:786–96. PubMed

Schoels M, Aletaha D, Funovits J. et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441–7. PubMed

Smolen JS, Braun J, Dougados M. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16. PubMed PMC

Michelsen B, Sexton J, Smolen JS. et al. Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 2018;77:1736–41. PubMed

Schoels MM, Aletaha D, Alasti F, Smolen JS.. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811–8. PubMed

Vandenbroucke JP, von Elm E, Altman DG. et al.; for the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297. PubMed PMC

Ørnbjerg LM, Linde L, Georgiadis S. et al. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration. Semin Arthritis Rheum 2022;56:152081. PubMed

Fries JF, Spitz PW, Young DY.. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789–93. PubMed

Wood AM, White IR, Royston P.. How should variable selection be performed with multiply imputed data? Stat Med 2008;27:3227–46. PubMed

Heinze G, Wallisch C, Dunkler D.. Variable selection – a review and recommendations for the practicing statistician. Biometr J 2018;60:431–49. PubMed PMC

Hanley JA, McNeil BJ.. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36. PubMed

Christiansen SN, Ørnbjerg LM, Rasmussen SH. et al. European bio-naïve spondyloarthritis patients initiating TNFi: time trends in baseline characteristics, treatment retention and response. Rheumatology (Oxford) 2022;61:3799–807. PubMed

Iervolino S, Di Minno MND, Peluso R. et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol 2012;39:568–73. PubMed

Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S.. Does age matter in psoriatic arthritis? A narrative review. J Rheumatol 2022;49:1085–91. PubMed

Gratacós J, Casado E, Real J, Torre-Alonso JC.. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007;66:493–7. PubMed PMC

Skougaard M, Jørgensen TS, Rifbjerg-Madsen S. et al. Relationship between fatigue and inflammation, disease duration, and chronic pain in psoriatic arthritis: an observational DANBIO Registry Study. J Rheumatol 2020;47:548–52. PubMed

Edwards RR, Bingham CO, Bathon J, Haythornthwaite JA.. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Care Res (Hoboken) 2006;55:325–32. PubMed

Hammer HB, Uhlig T, Kvien TK, Lampa J.. Pain catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients. Arthritis Care Res 2018;70:703–12. PubMed

Sokka T, Häkkinen A, Krishnan E, Hannonen P.. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004;63:494–7. PubMed PMC

Young A, Dixey J, Kulinskaya E. et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the early RA study (ERAS). Ann Rheum Dis 2002;61:335–40. PubMed PMC

Behrens F, Cañete JD, Olivieri I. et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatol (Oxford) 2014;54:915–26. PubMed

Mease PJ, Gladman DD, Collier DH. et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 2019;71:1112–24. PubMed PMC

George MD, Baker JF, Ogdie A.. Comparative persistence of methotrexate and tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2020;47:826–34. PubMed PMC

Lindström U, Di Giuseppe D, Delcoigne B. et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheum Dis 2021;80:1410–8. PubMed PMC

Landgren AJ, Bilberg A, Eliasson B. et al. Cardiovascular risk factors are highly overrepresented in Swedish patients with psoriatic arthritis compared with the general population. Scand J Rheumatol 2020;49:195–9. PubMed

Kaine J, Song X, Kim G, Hur P, Palmer JB.. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative claims data. J Manag Care Spec Pharm 2019;25:122–32. PubMed PMC